ClinicalTrials.gg
RecruitingNCT02901184SPIRRITUpdated Oct 22, 2024

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

A Phase 3 interventional study of Spironolactone and Standard care in Heart Failure With Preserved Ejection Fraction, sponsored by Uppsala University. Recruiting at 78 sites in 2 countries. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-10-22.

Sponsored by Uppsala University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2017; still recruiting 8 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
50 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies testing spironolactone in Heart Failure — 3 open to participants now, 4 under way, 1 of them phase 3. Spironolactone · Heart Failure.

Planned enrollment
2nd of 30
2,000 · median 37
Started
2017
the only one that year
Phase 3
6 of 31
1 open now
Registered
25th of 31
by date

Among the 31 studies testing spironolactone in Heart Failure, this one is the 2nd largest by planned enrollment of the 30 interventional ones that give a count, is the only one that started in 2017, is one of 6 in phase 3, and was the 25th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

3 of the 31 studies testing spironolactone in Heart Failure are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About spironolactone

Spironolactone: first FDA approval 1960 (ALDACTONE), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 50 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing spironolactone in Heart Failure, or all of them as a file.
02

Study summary

Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will not be studied by industry.

SPIRRIT is a unique Registry-Randomized Clinical Trial (RRCT) that will test the hypothesis that spironolactone plus standard of care compared to standard of care alone reduces the composite of CV mortality and HF hospitalization as follows:

Population: HFPEF patients in the Swedish Heart Failure Registry and HFPEF patients in US. HFPEF defined as symptoms/signs of HF, elevated NTproBNP (B-type Natriuretic Peptide; N-terminal pro b-type Natriuretic Peptide) and EF>=40%. Intervention and control: Randomized 1:1 to intervention: spironolactone + usual care vs. control: usual care alone.

Outcome: Primary outcome cardiovascular death or time to HF hospitalization. Secondary outcomes include hospitalization for various causes, adverse events and treatment adherence. In Sweden outcomes are obtained automatically by linking with the Population, Patient and Drug Dispensed Registries. In the US, outcomes will be reported by sites and supplemented by data from a call center. The trial is event-driven with enrollment 7 years and study duration 9 years. For the primary outcome (CV Death or first HF hospitalization) with an event target of 721 events the sample size requires 1985 patients conservatively rounded to approximately 2000 patients.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction

Browse trials for

04

Who can participate

Ages eligible
50 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Age ≥50 years
  • Stable heart failure defined by symptoms and signs of heart failure as judged by local Investigator
  • (LVEF) ≥40% recorded in last 12 months (stratified to max 2/3rd in either 40-49% or ≥50% group)
  • Elevated natriuretic peptide levels, as defined by any of the following:

    1. most recent NT-proBNP >300 ng/L (or BNP>100 pg/mL) in sinus rhythm at time of blood sampling; adjustments may be made for according to table 3.
    2. most recent NT-proBNP >750 ng/L (or BNP >250 pg/mL) in atrial fibrillation at time of blood sampling; adjustments may be made for BMI according to table 3.
    3. NT-proBNP >1200 ng/L (or BNP >400 pg/mL) within the last 12 months even if most recent value is lower.
  • Regular use of loop diuretics, defined as daily or most days of the week
  • Class II-IV

Exclusion criteria

Exclusion Criteria:

Previously enrolled in this study

  • Known \< 40% ever
  • Current absolute indication or for MRA (mineral receptor antagonist) in judgement of Investigator
  • Known chronic liver disease
  • Probable alternative explanations for symptoms:

    • Known primary cardiomyopathy (hypertrophic, constrictive, restrictive, infiltrative, congenital)
    • Primary hemodynamically significant valve disease
    • Right-sided HF not due to left-sided HF
    • Significant chronic pulmonary disease defined by Investigator or by requirement for home O2
    • Symptomatic anemia, defined as \< 10 g/dL (100 g/L )
  • Heart transplant or LVAD (left ventricular assist device) recipient
  • Presence of cardiac resynchronization therapy (CRT) device
  • Systolic blood pressure \<90 or >160 mmHg
  • K (potassium) >5.0 mmol/L
  • (estimated glomerular filtration rate) by MDRD (Modification of Diet in Renal Disease) \< 30 ml/min/1.73m2 or creatinine > 2.5 mg/dL (221 µmol/L )
  • Current lithium use
  • Current dialysis
  • Actual or potential for pregnancy
  • Participation in another interventional clinical trial where a mineralocorticoid receptor antagonist is studied
  • Any condition that in the opinion of the Investigator may interfere with adherence to trial protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Active comparator
    Spironolactone treatment

    Spironolactone will be prescribed by the Investigator and filled by patient at conventional pharmacies as 25 mg tablets. The treatment will be on top of standard care. Initial dose is 25 mg/day, which will be increased to target dose 50 mg/day if tolerated. Eplerenone can be prescribed if spironolactone is not tolerated.

    Drug: Spironolactone

  • Placebo comparator
    Standard care alone

    Patients in the control arm will get the standard care alone

    Other: Standard care

Interventions

  • Treatment with Spironolactone tablets on top of standard care

  • OtherStandard care

    Standard care does not involve Spironolactone

06

What researchers measure

Primary outcomes

  1. Incidence rate for total heart failure (HF) hospitalizations or cardiovascular (CV) death

    Sweden: Information on Death from the Swedish Causes of death registry and information on hospitalization collected from Swedish Patient Registry US: Collected in eCRF or via call center interview

    Time frame: Collected at data base lock, five (5) years after study start (US: continuously until 5 years after study start)

Secondary outcomes

  1. Time to CV Death or first HF hospitalization

    Sweden: Information on Death from the Swedish Causes of death registry US: Collected in eCRF or via call center interview

    Time frame: Collected at data base lock, five (5) years after study start (US: continuously until 5 years after study start)

  2. Time to CV Death

    Sweden: Information on Death from the Swedish Causes of death registry US: Collected in eCRF or via call center interview

    Time frame: Collected at data base lock, five (5) years after study start (US: continuously until 5 years after study start)

  3. Incidence rate for total HF hospitalizations

    Sweden: Information on Death from the Swedish Causes of death registry and information on hospitalization collected from Swedish Patient Registry. US: Collected in eCRF or via call center interview

    Time frame: Collected at data base lock, five (5) years after study start (US: continuously until 5 years after study start)

  4. Time to HF hospitalizations

    Sweden: Information on information on hospitalization collected from Swedish Patient Registry. US: Collected in eCRF or via call center interview

    Time frame: Collected at data base lock, five (5) years after study start (US: continuously until 5 years after study start)

  5. Time to all-cause mortality

    Sweden: Information on Death from the Swedish Causes of death registry. US: Collected in eCRF or via call center interview

    Time frame: Collected at data base lock, five (5) years after study start

  6. Incidence rate for all-cause hospitalizations

    Sweden: Information on information on hospitalization collected from Swedish Patient Registry. US: Collected in eCRF or via call center interview

    Time frame: Collected at data base lock, five (5) years after study start (US: continuously until 5 years after study start)

  7. Time to all-cause hospitalizations

    Sweden: Information on information on hospitalization collected from Swedish Patient Registry. US: Collected in eCRF or via call center interview

    Time frame: Collected at data base lock, five (5) years after study start (US: continuously until 5 years after study start)

  8. Incidence rate for all-cause hospitalizations or all-cause mortality

    Sweden: Information on Death from the Swedish Causes of death registry and information on hospitalization collected from Swedish Patient Registry. US: Collected in eCRF or via call center interview

    Time frame: Collected at data base lock, five (5) years after study start (US: continuously until 5 years after study start)

07

Study locations

29 of 78 sites recruiting
  • Advanced Cardiovascular LLC
    Alexander City, Alabama 35010, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Banner - University Medical Group
    Tucson, Arizona 85724, United States
    Terminated

    Not enrolling at this site — choose another above.

  • MedStar Cardiovascular Research Network
    Washington, District of Columbia 20010, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Howard University Hospital
    Washington, District of Columbia 20060, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Piedmont Atlanta Hospital
    Atlanta, Georgia 30309, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Wellstar Health System, Inc.
    Marietta, Georgia 30060, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Queens Medical Center
    Honolulu, Hawaii 96813, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Fox Valley Clinical Research Center, LLC
    Aurora, Illinois 60506-1400, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Alexian Brothers Medical Center
    Elk Grove Village, Illinois 60007, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Methodist Medical Center of Illinois
    Peoria, Illinois 61636, United States
    Terminated

    Not enrolling at this site — choose another above.

  • St. Vincent Medical Group
    Indianapolis, Indiana 46260, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Ochsner Medical Center
    New Orleans, Louisiana 85724, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Shady Grove Adventist Hospital
    Rockville, Maryland 20850, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Pentucket Medical Associates
    Haverhill, Massachusetts 01830, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Charles River Medical Associates
    Natick, Massachusetts 01760, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Newton-Wellesley Hospital
    Newton, Massachusetts 02462, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of Michigan Medical Center
    Ann Arbor, Michigan 48109, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Ascension Genesys Hospital
    Grand Blanc, Michigan 48439, United States
    Terminated

    Not enrolling at this site — choose another above.

  • The Heart House Haddon Heights
    Haddon Heights, New Jersey 08035, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Rutgers University - Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of New Mexico Health Science Center
    Albuquerque, New Mexico 87131, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University at Buffalo
    Buffalo, New York 14203, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Northwell Health - Manhasset
    Manhasset, New York 11030, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Mount Sinai Medical Cente
    New York, New York 10029, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Mid Carolina Cardiology Research
    Charlotte, North Carolina 28204, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Duke University
    Durham, North Carolina 27710-4000, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45267-0542, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Penn State Milton S Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Stern Cardiovascular Center
    Germantown, Tennessee 38138, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Baylor University Medical Center
    Dallas, Texas 75246, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of Miami Hospital
    Miami, Texas 33136, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Angereds närsjukhus
    Angered, Sweden
    Terminated

    Not enrolling at this site — choose another above.

  • Falu lasarett
    Falun, Sweden
    Recruiting
    • Fahed Sulaiman · Contact
  • Närsjukvården i Finspång
    Finspång, Sweden
    Terminated

    Not enrolling at this site — choose another above.

  • Vårdcentralen Centrum i Flen
    Flen, Sweden
    Recruiting
    • Kaj Possler · Contact
  • Sahgrenska University Hospital Östra
    Göteborg, Sweden
    Recruiting
    • Mikael Fu · Contact
    • Mikael Fu · Principal investigator
  • Sahlgrenska Universitetssjukhuset
    Göteborg, Sweden
    Recruiting
    • Charlotta Ljungman · Contact
  • Hemse Vårdcentral
    Hemse, Sweden
    Recruiting
    • Ann Hovland-Tånneryd · Contact
  • Karolinska University Hospital
    Huddinge, Sweden
    Recruiting
    • Lars H Lund · Contact
    • Lars H Lund · Principal investigator
  • Länssjukhuset Ryhov
    Jönköping, 55185, Sweden
    Recruiting
    • Patric Karlström · Contact
  • Blekingesjukhuset
    Karlskrona, 37185, Sweden
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hjärtmottagningen, Centralsjukhuset
    Karlstad, 65230, Sweden
    Recruiting
    • Edit Floderer · Contact
  • Centralsjukhuset Kristianstad
    Kristianstad, Sweden
    Terminated

    Not enrolling at this site — choose another above.

  • Västmanlands sjukhus Köping
    Köping, Sweden
    Recruiting
    • Emöke Fodor · Contact
  • Lasarettet i Landskrona
    Landskrona, Sweden
    Recruiting
    • Fredrik Kymle · Contact
  • Skaraborgs sjukhus i Lidköping
    Lidköping, Sweden
    Recruiting
    • Magnus Peterson · Contact
  • Linköpings Universitetssjukhus
    Linköping, 58185, Sweden
    Recruiting
    • Henriette van der Wal · Contact
  • VO Akut- och internmedicin, Skånes Universitetssjukhus
    Lund, 22185, Sweden
    Terminated

    Not enrolling at this site — choose another above.

  • Capio Citykliniken
    Lund, Sweden
    Recruiting
    • Carl-Johan Lindholm · Contact
  • FO Kranskärl/Svikt, Skånes Universitetssjukhus
    Lund, Sweden
    Recruiting
    • Grunde Gjesdal · Contact
  • Hjärtavdelningen, Skånes Universitetssjukhus
    Malmö, 20502, Sweden
    Terminated

    Not enrolling at this site — choose another above.

  • Kliniska forskningsenheten Skånes Universitetssjukhus
    Malmö, Sweden
    Recruiting
    • Patrik Svenson · Principal investigator
  • Mariefreds Vårdcentral
    Mariefred, Sweden
    Recruiting
    • Tobias Reitberger · Contact
    • Tobias Reitberger · Principal investigator
  • Sahlgrenska University Hospital Mölndal
    Mölndal, Sweden
    Recruiting
    • Pär Parén · Contact
    • Pär Parén · Principal investigator
  • Kardiologikliniken, Vrinnevisjukhuset
    Norrköping, 60182, Sweden
    Recruiting
    • Dimitros Ftakas · Contact
  • Oskarshamns sjukhus
    Oskarshamn, Sweden
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Skellefteå lasarett
    Skellefteå, Sweden
    Recruiting
    • Lars Gustafsson · Contact
  • Karolinska University Hospital
    Solna, Sweden
    Recruiting
    • Lars H Lund · Contact
    • Lars H Lund · Principal investigator
  • VO Kardiologi, Södersjukhuset AB
    Stockholm, 11883, Sweden
    Recruiting
    • Carin Corovic Cabrera · Contact
  • Capio S:t Görans sjukhus AB
    Stockholm, Sweden
    Recruiting
    • Majid Jourak · Contact
  • Danderyds sjukhus AB
    Stockholm, Sweden
    Recruiting
    • Jonas Spaak · Contact
  • Länssjukhuset Sundsvall-Härnösand
    Sundsvall, Sweden
    Recruiting
    • Mohammad Kavianipour · Contact
  • Sundsvalls Vårdcentral
    Sundsvall, Sweden
    Terminated

    Not enrolling at this site — choose another above.

  • Södertälje sjukhus
    Södertälje, Sweden
    Terminated

    Not enrolling at this site — choose another above.

  • Uppsala University Hospital, Cardiology dept
    Uppsala, Sweden
    Recruiting
    • Tymon Pol, MD, Phd · Contact
  • Uppsala University Hospital, Internal Medicine dept
    Uppsala, Sweden
    Recruiting
    • Michael Dimberg · Contact
  • Medicinkliniken, Hallands sjukhus
    Varberg, 43281, Sweden
    Recruiting
    • Petru Tutuainu · Contact
  • Västerviks sjukhus
    Västervik, Sweden
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Västmanlands sjukhus Västerås
    Västerås, Sweden
    Recruiting
    • Ingmar Lönnberg · Contact
    • Ingmar Lönnberg · Principal investigator
  • Hälsostaden Ängelholms sjukhus
    Ängelholm, Sweden
    Terminated

    Not enrolling at this site — choose another above.

  • Örebro University Hospital
    Örebro, Sweden
    Recruiting
    • Barna Szabó · Contact
    • Barna Szabó · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2017 (actual). Primary completion is estimated for Dec 2026, 109 months after the start.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 109 months is above that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2016
First posted
Sep 15, 2016
StartActual
Nov 23, 2017
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02901184
Lead sponsor
Uppsala University
Collaborators
Karolinska University, Duke Clinical Research Institute, National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Sponsor
First posted
Sep 15, 2016
Start date
Nov 23, 2017
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 22, 2024

Study contacts

Anna Gustavsson (SWE)
Contact
anna.gustavsson@ucr.uu.se
+46186110181
Will Simmons (US)
Contact
will.simmons@duke.edu
919-668-0541
Lars H Lund, MD, PhD
principal investigator · Karolinska Institutet
Bertram Pitt
principal investigator · University of Michigan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Spironolactone

Start the discussion